Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage

Taishi Yamashita, Hideto Tamura, Chikako Satoh, Eiji Shinya, Hidemi Takahashi, Lieping Chen, Asaka Kondo, Takashi Tsuji, Kazuo Dan, Kiyoyuki Ogata

Research output: Contribution to journalArticle

Abstract

Purpose: B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this study was to investigate whether functional B7.2 and B7-H2 molecules are expressed on myeloma cells and, if so, whether they are associated with pathophysiology in myeloma. Experimental Design: The expression of B7.2 and B7-H2 molecules on normal plasma and neoplastic (myeloma) plasma cells was analyzed. The cell proliferation and immunomodulatory function of myeloma cells related to B7.2 and B7-H2 expression were examined. Results: Human myeloma cell lines commonly expressed B7.2 and B7-H2 molecules. B7.2 expression on plasma cells was more common in myeloma patients (n = 35) compared with that in patients with monoclonal gammopathy of unknown significance (n = 12) or hematologically normal individuals (n = 10). Plasma cells expressing B7-H2 were observed in myeloma patients alone, although rarely. Patients whose myeloma cells showed high B7.2 expression were more anemic and thrombocytopenic than other myeloma patients. The expression of these molecules was induced or augmented by cultivating myeloma cells with autologous stroma cells or tumor necrosis factor-α, a key cytokine in myeloma biology. Cell proliferation was more rapid in the B7.2 + and B7-H2 + populations compared with the B7.2 - and B7-H2 - populations, respectively, in the human myeloma cell lines examined. B7.2 and B7-H2 molecules on myeloma cells induced normal CD4 + T cells to proliferate and produce soluble factors, including interleukin-10 that stimulate myeloma cell proliferation. Conclusions: Functional B7.2 and B7-H2 molecules detected on myeloma cells may be involved in the pathophysiology of myeloma.

Original languageEnglish (US)
Pages (from-to)770-777
Number of pages8
JournalClinical Cancer Research
Volume15
Issue number3
DOIs
StatePublished - Feb 1 2009

Fingerprint

B7 Antigens
Growth
Cell Proliferation
Plasma Cells
Cell Line
Paraproteinemias
Antigen-Presenting Cells
Multiple Myeloma
Interleukin-10
Population
Research Design
Tumor Necrosis Factor-alpha
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yamashita, T., Tamura, H., Satoh, C., Shinya, E., Takahashi, H., Chen, L., ... Ogata, K. (2009). Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. Clinical Cancer Research, 15(3), 770-777. https://doi.org/10.1158/1078-0432.CCR-08-0501

Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. / Yamashita, Taishi; Tamura, Hideto; Satoh, Chikako; Shinya, Eiji; Takahashi, Hidemi; Chen, Lieping; Kondo, Asaka; Tsuji, Takashi; Dan, Kazuo; Ogata, Kiyoyuki.

In: Clinical Cancer Research, Vol. 15, No. 3, 01.02.2009, p. 770-777.

Research output: Contribution to journalArticle

Yamashita, T, Tamura, H, Satoh, C, Shinya, E, Takahashi, H, Chen, L, Kondo, A, Tsuji, T, Dan, K & Ogata, K 2009, 'Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage', Clinical Cancer Research, vol. 15, no. 3, pp. 770-777. https://doi.org/10.1158/1078-0432.CCR-08-0501
Yamashita, Taishi ; Tamura, Hideto ; Satoh, Chikako ; Shinya, Eiji ; Takahashi, Hidemi ; Chen, Lieping ; Kondo, Asaka ; Tsuji, Takashi ; Dan, Kazuo ; Ogata, Kiyoyuki. / Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 3. pp. 770-777.
@article{0e5c36911381479d9d4dcbd8154fb553,
title = "Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage",
abstract = "Purpose: B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this study was to investigate whether functional B7.2 and B7-H2 molecules are expressed on myeloma cells and, if so, whether they are associated with pathophysiology in myeloma. Experimental Design: The expression of B7.2 and B7-H2 molecules on normal plasma and neoplastic (myeloma) plasma cells was analyzed. The cell proliferation and immunomodulatory function of myeloma cells related to B7.2 and B7-H2 expression were examined. Results: Human myeloma cell lines commonly expressed B7.2 and B7-H2 molecules. B7.2 expression on plasma cells was more common in myeloma patients (n = 35) compared with that in patients with monoclonal gammopathy of unknown significance (n = 12) or hematologically normal individuals (n = 10). Plasma cells expressing B7-H2 were observed in myeloma patients alone, although rarely. Patients whose myeloma cells showed high B7.2 expression were more anemic and thrombocytopenic than other myeloma patients. The expression of these molecules was induced or augmented by cultivating myeloma cells with autologous stroma cells or tumor necrosis factor-α, a key cytokine in myeloma biology. Cell proliferation was more rapid in the B7.2 + and B7-H2 + populations compared with the B7.2 - and B7-H2 - populations, respectively, in the human myeloma cell lines examined. B7.2 and B7-H2 molecules on myeloma cells induced normal CD4 + T cells to proliferate and produce soluble factors, including interleukin-10 that stimulate myeloma cell proliferation. Conclusions: Functional B7.2 and B7-H2 molecules detected on myeloma cells may be involved in the pathophysiology of myeloma.",
author = "Taishi Yamashita and Hideto Tamura and Chikako Satoh and Eiji Shinya and Hidemi Takahashi and Lieping Chen and Asaka Kondo and Takashi Tsuji and Kazuo Dan and Kiyoyuki Ogata",
year = "2009",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-08-0501",
language = "English (US)",
volume = "15",
pages = "770--777",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage

AU - Yamashita, Taishi

AU - Tamura, Hideto

AU - Satoh, Chikako

AU - Shinya, Eiji

AU - Takahashi, Hidemi

AU - Chen, Lieping

AU - Kondo, Asaka

AU - Tsuji, Takashi

AU - Dan, Kazuo

AU - Ogata, Kiyoyuki

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Purpose: B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this study was to investigate whether functional B7.2 and B7-H2 molecules are expressed on myeloma cells and, if so, whether they are associated with pathophysiology in myeloma. Experimental Design: The expression of B7.2 and B7-H2 molecules on normal plasma and neoplastic (myeloma) plasma cells was analyzed. The cell proliferation and immunomodulatory function of myeloma cells related to B7.2 and B7-H2 expression were examined. Results: Human myeloma cell lines commonly expressed B7.2 and B7-H2 molecules. B7.2 expression on plasma cells was more common in myeloma patients (n = 35) compared with that in patients with monoclonal gammopathy of unknown significance (n = 12) or hematologically normal individuals (n = 10). Plasma cells expressing B7-H2 were observed in myeloma patients alone, although rarely. Patients whose myeloma cells showed high B7.2 expression were more anemic and thrombocytopenic than other myeloma patients. The expression of these molecules was induced or augmented by cultivating myeloma cells with autologous stroma cells or tumor necrosis factor-α, a key cytokine in myeloma biology. Cell proliferation was more rapid in the B7.2 + and B7-H2 + populations compared with the B7.2 - and B7-H2 - populations, respectively, in the human myeloma cell lines examined. B7.2 and B7-H2 molecules on myeloma cells induced normal CD4 + T cells to proliferate and produce soluble factors, including interleukin-10 that stimulate myeloma cell proliferation. Conclusions: Functional B7.2 and B7-H2 molecules detected on myeloma cells may be involved in the pathophysiology of myeloma.

AB - Purpose: B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this study was to investigate whether functional B7.2 and B7-H2 molecules are expressed on myeloma cells and, if so, whether they are associated with pathophysiology in myeloma. Experimental Design: The expression of B7.2 and B7-H2 molecules on normal plasma and neoplastic (myeloma) plasma cells was analyzed. The cell proliferation and immunomodulatory function of myeloma cells related to B7.2 and B7-H2 expression were examined. Results: Human myeloma cell lines commonly expressed B7.2 and B7-H2 molecules. B7.2 expression on plasma cells was more common in myeloma patients (n = 35) compared with that in patients with monoclonal gammopathy of unknown significance (n = 12) or hematologically normal individuals (n = 10). Plasma cells expressing B7-H2 were observed in myeloma patients alone, although rarely. Patients whose myeloma cells showed high B7.2 expression were more anemic and thrombocytopenic than other myeloma patients. The expression of these molecules was induced or augmented by cultivating myeloma cells with autologous stroma cells or tumor necrosis factor-α, a key cytokine in myeloma biology. Cell proliferation was more rapid in the B7.2 + and B7-H2 + populations compared with the B7.2 - and B7-H2 - populations, respectively, in the human myeloma cell lines examined. B7.2 and B7-H2 molecules on myeloma cells induced normal CD4 + T cells to proliferate and produce soluble factors, including interleukin-10 that stimulate myeloma cell proliferation. Conclusions: Functional B7.2 and B7-H2 molecules detected on myeloma cells may be involved in the pathophysiology of myeloma.

UR - http://www.scopus.com/inward/record.url?scp=61349148810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349148810&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-0501

DO - 10.1158/1078-0432.CCR-08-0501

M3 - Article

VL - 15

SP - 770

EP - 777

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -